- Home
- COSM vs NEUP Comparison
COSM vs NEUP Comparison
Compare COSM & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COSM
- NEUP
- Stock Information
- Founded
- COSM 2009
- NEUP 1996
- Country
- COSM United States
- NEUP United States
- Employees
- COSM N/A
- NEUP N/A
- Industry
- COSM Other Pharmaceuticals
- NEUP
- Sector
- COSM Health Care
- NEUP
- Exchange
- COSM Nasdaq
- NEUP Nasdaq
- Market Cap
- COSM 12.3M
- NEUP 12.7M
- IPO Year
- COSM 2013
- NEUP N/A
- Fundamental
- Price
- COSM $0.80
- NEUP $7.95
- Analyst Decision
- COSM
- NEUP Strong Buy
- Analyst Count
- COSM 0
- NEUP 1
- Target Price
- COSM N/A
- NEUP $21.00
- AVG Volume (30 Days)
- COSM 1.5M
- NEUP 37.2K
- Earning Date
- COSM 08-18-2025
- NEUP 08-26-2025
- Dividend Yield
- COSM N/A
- NEUP N/A
- EPS Growth
- COSM N/A
- NEUP N/A
- EPS
- COSM N/A
- NEUP 0.00
- Revenue
- COSM $53,554,457.00
- NEUP $15,662,715.00
- Revenue This Year
- COSM $28.14
- NEUP N/A
- Revenue Next Year
- COSM N/A
- NEUP N/A
- P/E Ratio
- COSM N/A
- NEUP $4,679.22
- Revenue Growth
- COSM N/A
- NEUP N/A
- 52 Week Low
- COSM $0.28
- NEUP $2.90
- 52 Week High
- COSM $1.58
- NEUP $126.00
- Technical
- Relative Strength Index (RSI)
- COSM 56.06
- NEUP N/A
- Support Level
- COSM $0.74
- NEUP N/A
- Resistance Level
- COSM $1.28
- NEUP N/A
- Average True Range (ATR)
- COSM 0.18
- NEUP 0.00
- MACD
- COSM -0.01
- NEUP 0.00
- Stochastic Oscillator
- COSM 36.02
- NEUP 0.00
About COSM Cosmos Health Inc.
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.